Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
ApexOnco Front Page
Recent articles
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
The company will be the first to take a FcRH5-targeting project into phase 3.
